Health and Me

Ishita Roy

Nebokitug Explained: Antibody Used To Treat A Rare Liver Disease

For people living with primary sclerosing cholangitis or PSC, medical options have always been painfully limited. Until now, there has been no approved drug that can slow the disease itself. Treatment has mostly meant managing symptoms and waiting, often for years, until a liver transplant becomes the only option. That is why new results around a monoclonal antibody called <span>nebokitug</span> are being seen as a turning point.

Researchers from the University of California Davis have reported promising findings from a Phase 2 clinical trial showing that nebokitug appears safe and may actually reduce liver inflammation and scarring. The study was published in the American Journal of Gastroenterology and has brought cautious optimism to both doctors and patients.

PSC is a rare, long-term liver disease that mainly affects the bile ducts. These ducts act like tiny pipelines that carry bile from the liver to the small intestine, where it helps digest fats. In PSC, these ducts become inflamed, damaged, and scarred over time. As they narrow, bile starts backing up in the liver, slowly causing liver injury.

Many people with PSC also have inflammatory bowel disease, especially ulcerative colitis. This strong link has led researchers to believe that ongoing gut inflammation may trigger immune reactions that damage the liver as well. Symptoms can range from extreme tiredness and itching to yellowing of the skin and eyes. Some patients have no symptoms at all in the early stages, which makes the disease harder to catch.

<h2>Why Treatment Has Been So Difficult</h2>

One of the biggest challenges with PSC is that doctors have not had a way to stop the scarring process itself. Once fibrosis sets in, it slowly progresses and increases the risk of liver failure and bile duct cancer. While medications can help with itching or infections, they do not change the course of the disease. This gap in treatment is what makes the nebokitug study so important.

Nebokitug is a lab-made antibody designed to block a protein called CCL24. This protein plays a key role in driving inflammation and fibrosis in the liver. In people with PSC, CCL24 levels are higher than normal and are found around the bile ducts where damage is most severe.

By blocking CCL24, nebokitug aims to calm the immune response and slow down the scarring process. Earlier lab and animal studies suggested this approach could work. The new trial is one of the first to test this idea in people with PSC.

The Phase 2 study included 76 patients from five countries. Participants received either one of two doses of nebokitug or a placebo through an IV every three weeks for 15 weeks. The main goal was to check safety, since this was still an early-stage trial.

The results were encouraging. Nebokitug was found to be safe and well tolerated. More importantly, patients who already had more advanced liver scarring showed improvements in liver stiffness and markers linked to fibrosis when compared to those on placebo. These changes suggest that the drug may be doing more than just easing symptoms.

Experts involved in the study say these findings could change the future of PSC care. Reducing inflammation and fibrosis could slow disease progression and delay or even prevent the need for a transplant in some patients. While larger trials are still needed, nebokitug represents one of the strongest signals yet that PSC may finally have a disease-modifying treatment on the horizon.

Health Conditions A-Z

health

medical breakthrough

live disease

breakthrough

nebokitug

rare liver disease

health and wellness

At 66, Emma Thompson Lost 8kg by Ditching Diet Culture; Why Say This Approach Works

Adenovirus Cases Rise In UK, Health Authorities On Alert

Health & Wellness

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

For people living with primary sclerosing cholangitis or PSC, medical options have always been painfully limited. Until now, there has been no approved drug that can slow the disease itself. Treatment has mostly meant managing symptoms and waiting, often for years, until a liver transplant becomes the only option. That is why new results around a monoclonal antibody called nebokitug are being seen as a turning point.Researchers from the University of California Davis have reported promising findings from a Phase 2 clinical trial showing that nebokitug appears safe and may actually reduce liver inflammation and scarring. The study was published in the American Journal of Gastroenterology and has brought cautious optimism to both doctors and patients.What Exactly Is PSC?PSC is a rare, long-term liver disease that mainly affects the bile ducts. These ducts act like tiny pipelines that carry bile from the liver to the small intestine, where it helps digest fats. In PSC, these ducts become inflamed, damaged, and scarred over time. As they narrow, bile starts backing up in the liver, slowly causing liver injury.Many people with PSC also have inflammatory bowel disease, especially ulcerative colitis. This strong link has led researchers to believe that ongoing gut inflammation may trigger immune reactions that damage the liver as well. Symptoms can range from extreme tiredness and itching to yellowing of the skin and eyes. Some patients have no symptoms at all in the early stages, which makes the disease harder to catch.Why Treatment Has Been So DifficultOne of the biggest challenges with PSC is that doctors have not had a way to stop the scarring process itself. Once fibrosis sets in, it slowly progresses and increases the risk of liver failure and bile duct cancer. While medications can help with itching or infections, they do not change the course of the disease. This gap in treatment is what makes the nebokitug study so important.How Nebokitug WorksNebokitug is a lab-made antibody designed to block a protein called CCL24. This protein plays a key role in driving inflammation and fibrosis in the liver. In people with PSC, CCL24 levels are higher than normal and are found around the bile ducts where damage is most severe.By blocking CCL24, nebokitug aims to calm the immune response and slow down the scarring process. Earlier lab and animal studies suggested this approach could work. The new trial is one of the first to test this idea in people with PSC.What the Trial FoundThe Phase 2 study included 76 patients from five countries. Participants received either one of two doses of nebokitug or a placebo through an IV every three weeks for 15 weeks. The main goal was to check safety, since this was still an early-stage trial.The results were encouraging. Nebokitug was found to be safe and well tolerated. More importantly, patients who already had more advanced liver scarring showed improvements in liver stiffness and markers linked to fibrosis when compared to those on placebo. These changes suggest that the drug may be doing more than just easing symptoms.Experts involved in the study say these findings could change the future of PSC care. Reducing inflammation and fibrosis could slow disease progression and delay or even prevent the need for a transplant in some patients. While larger trials are still needed, nebokitug represents one of the strongest signals yet that PSC may finally have a disease-modifying treatment on the horizon.